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Abstract:Myasthenia gravis is the best known autoimmune disease
associated with thymomas, but other conditions can be found in
patients with thymic tumors, including some that affect the central
nervous system (CNS). We have become particularly interested in
patients who have acquired neuromyotonia, the rare Morvan disease,
or limbic encephalitis. Neuromyotonia mainly involves the periph-
eral nerves, Morvan disease affects both the peripheral nervous
system and CNS, and limbic encephalitis is specific to the CNS.
Many of these patients have voltage-gated potassium channel auto-
antibodies. All three conditions can be associated with thymomas
and may respond to surgical removal of the underlying tumor
together with immunotherapies and symptomatic treatments. Herein,
we review the results of our recent studies that show that voltage-
gated potassium channel autoantibodies are not principally directed
against the potassium channels themselves but in some patients are
directed against a protein that is complexed with potassium channels
in both the peripheral nervous system and CNS, contactin-2 associ-
ated protein (Caspr2). These antibodies are common in the subgroup
of patients with thymic malignancies.
Key Words: Thymoma, VGKC antibody, VGKC complex, Neuro-
myotonia, Caspr2.
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The presence of autoantibodies to proteins that are sharedbetween tumors and the nervous system is well known.
Such paraneoplastic or “onconeural” antibodies are usually
directed at intracellular proteins and are unlikely, therefore, to
be pathogenic, but the detection of the antibody helps identify
the presence of a tumor. In thymomas, such antibodies
include those against titin in myasthenia gravis (MG)1 and
against a variety of neuronal antigens such as Hu and CV2/
CRMP5 in other cases.2
By contrast, autoantibodies that are causative are usu-
ally directed toward membrane receptors or ion channels.
MG is caused in most patients by antibodies to acetylcholine
receptors (AChRs3) that lead to loss of AChRs from the
neuromuscular junction. Neuromyotonia (NMT) is due to
motor nerve hyperexcitability that leads to muscle fascicula-
tions and cramps. A proportion of patients have antibodies
that appear to be directed against brain tissue-derived volt-
age-gated potassium channels (VGKCs) that control the ax-
onal membrane potential.4,5 VGKC antibody titers are rela-
tively low in NMT.
Morvan disease is a rare condition first described in
1876 but until recently hardly mentioned outside the French
literature.6 The patients exhibit NMT plus autonomic distur-
bance (such as excessive sweating, constipation, and cardiac
arrhythmias) and central nervous system (CNS) involvement
that includes insomnia and confusion. Many reported cases
are associated with thymomas,7,8 although other tumors have
been identified.9 Morvan disease can also be nonparaneoplas-
tic10 and occasionally self-limiting.11 Antibodies to VGKCs
have been found at moderately high titers in a few reported
cases of MoS.9
Limbic encephalitis (LE) was first described in the
1960s12 in association with small cell lung cancer. LE pa-
tients develop a subacute onset of amnesia, which is often
profound, and is usually accompanied by seizures and psy-
chiatric disturbances. Patients traditionally have magnetic
resonance imaging evidence of inflammation within the me-
dial temporal lobes. Although originally considered a para-
neoplastic condition,13 there are increasing numbers of pa-
tients with nonparaneoplastic LE, and many of these have
VGKC antibodies at high titers.14–16 A relatively specific
feature in these cases is the presence of a serum hyponatre-
mia. The VGKC antibody titers fall when the patients are
treated in parallel with clinical improvements.
NMT, MoS, and LE have all been described in patients
with MG and thymoma,17,18 and in patients with thymoma
without MG,18 usually with VGKC antibodies. These condi-
tions can also occur with other tumors (principally small cell
lung cancer) and other antibodies, but in this study, we will
only discuss the patients with VGKC antibodies and review
recent data on the specificity of antibodies to VGKCs.
MATERIALS AND METHODS
The data and methods are based on the results of studies
over a number of years, which are described in detail in Ref.
19. Patient serum samples were mainly referred for testing by
our clinical neuroimmunology service, and the clinical fea-
tures were obtained subsequently by questionnaires and dis-
cussion with the referring neurologists. VGKC antibodies
were measured by radioimmunoprecipitation of 125I--dend-
rotoxin-labeled VGKCs extracted from rabbit brain tissue.4,5
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The brain tissue extracts were made in 2% digitonin, a
detergent which is mild and does not dissociate protein
complexes. Some experiments were performed with addi-
tional sodium dodecyl sulfate (SDS), a harsher detergent. We
also transfected human embryonic kidney cells (HEK293)
cells with cDNAs for VGKC subunits (Kv1.1, 1.2, 1.6) or
contactin-2 associated protein (Caspr2) or Caspr2-EGFP. The
latter construct was made by fusing the cDNA for EGFP onto
the C-terminal end of the Caspr2 (see Ref. 19).
RESULTS
The patients to be discussed here were chosen on the
basis of their high VGKC-Abs (values 400 pM; normal
values 100 pM), because patients with high titers most
often have CNS disease. We will compare those patients with
thymomas or other tumors with those who did not have
detectable tumors. It should be made clear, therefore, that
many patients with thymomas and antibody-mediated dis-
eases, e.g., MG, do not have VGKC antibodies and would not
have been studied nor did we include patients with lower
VGKC-Ab titers.
Of the 82 patients to be described, 61 had LE, 5 had
MoS, and 16 had NMT. Six patients had thymomas including
one patient with MoS and five with NMT; one patient with
NMT had a metastatic endometrial carcinoma. The thymoma
classifications were obtained from the patients’ clinical records
and are given in Table 1. Eight of the remaining patients had past
histories of other tumors that appeared to be inactive at the time
of presentation of their VGKC-Ab–related diseases (five LE,
one MoS, and two NMT, see Ref. 19).
The results of their VGKC antibodies are shown in
Figure 1A; as expected from observations on smaller cohorts
or individual cases, those with NMT had relatively low
antibodies compared with those with LE, whereas the few
MoS cases had intermediate titers. Correspondingly, the an-
tibody titers in the patients with thymomas were lower than in
those without (Figure 1B).
A series of experiments were undertaken to define the
specificities of the antibodies for the VGKCs. The VGKCs
that bind 125I--dendrotoxin and are used for measuring
antibodies are tetramers composed of differing proportions of
Kv1.1, 1.2, 1.4, and 1.6. However, when we expressed these
Kv1 subunits individually or collectively in human embry-
onic kidney (HEK293) cells, we could not detect Kv1-
specific binding by immunofluorescence, a technique that we
now use for detecting antibodies to many other membrane
antigens such as the AChR (termed a cell-based assay; as in
Refs. 19–22). Moreover, there was no effect of the antibodies
from patients with high titers of VGKC antibodies on the
voltage-dependent currents in these cells (See Ref. 19).
We hypothesized that the antibodies might be binding,
instead, to other proteins that were part of the brain mem-
brane protein complexes that contain VGKCs. To investigate
this, we first added increasing amounts of harsh detergent,
SDS, to the VGKC assays. Although the binding of commer-
cial antibodies to Kv1.1 or 1.2 was not substantially affected
by 0.025% SDS, binding of the patients’ antibodies was
reduced to approximately 20% (Figure 1C). This suggested
FIGURE 1. A, Voltage-gated potassium channel
antibody (VGKC-Ab) titers in healthy controls
(HCs) and in neuromyotonia (NMT), Morvan dis-
ease (MoS), and limbic encephalitis (LE) patients.
B, VGKC-Ab titers in patients with and without
thymomas. C, The binding sites for patients’ anti-
bodies on 125I -dendrotoxin-labeled digitonin-
solubilized VGKC antibody complexes are more
sensitive to a low concentration of sodium dode-
cyl sulfate (SDS) than binding sites for Kv1.1 anti-
bodies. D, Healthy control sera (HC) do not show
binding to the surface of human embryonic kid-
ney cells expressing Caspr2. The Caspr2 was
tagged with enhanced green fluorescent protein
(Caspr2-EGFP) so that the transfected cells could
be identified. Some VGKC-Ab positive sera (1:100
dilution), including six of the seven sera from pa-
tients with thymomas, bound to Caspr2-trans-
fected cells.





M 71 Type B3, Stage 2
M 60 Type B2, Stage 2
F 53 Thymic carcinoma, Type B2, Stage 2
M 37 Type AB
M 49 Malignant metastatic thymoma
M 44 Malignant metastatic thymoma
F 74 Malignant metastatic thymoma, Type B2 with areas of B3
MG, myasthenia gravis.
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that the SDS had dissociated the target of the patients’
antibodies from the Kv1 channels. Work by others had shown
that proteins such as Caspr2, Lgi1, contactin-2, and
PSD95/93 were part of the Kv1 VGKC complexes.23 We
found that commercial antibodies to Caspr2 were able to
precipitate 125I--dendrotoxin-labeled VGKCs from digito-
nin extracts of rabbit brain. This showed that Caspr2 must be
part of the protein complex that contains VGKCs and sug-
gested that some patients might have antibodies to Caspr2
rather than to the VGKCs themselves.
Antibodies to Caspr2
To determine whether the patients had antibodies to
Caspr2, we expressed the protein in HEK293 cells and looked
for binding of the patients’ serum IgG to the unpermeabilized
cells. Healthy/disease control sera did not show binding
(Figure 1D, upper panels). Caspr2 was expressed on the cell
surface as demonstrated by binding of a commercial antibody
(not shown). Antibodies to Caspr2 were found in 19 of the 82
patients (23%; e.g., Figure 1D, lower panels). Caspr2 is
strongly expressed at the juxtaparanodes of myelinated axons
in the CNS and in the peripheral nerves (reviewed in Ref. 24).
Antibodies to Caspr2 in Thymoma
Of the 6 patients with thymomas, 5 had Caspr2-Abs,
compared with 13 of the 75 patients without thymomas
(Fisher’s exact test p  0.0005). The one patient with an
active endometrial carcinoma also had Caspr2-Abs. The di-
agnosis and clinical features of the patients with Caspr2
antibodies are shown in Table 2, which is divided between
those with and without tumors in Table 3.
DISCUSSION
Thymomas have been associated with MG for many
years, but more recently it has been clear that other
conditions can be found in these patients, including CNS
diseases that are likely due to specific antibodies. The most
striking clinical condition is Morvan disease, which is a
rare but highly interesting disorder in which patients suffer
from a combination of peripheral nervous system (NMT),
autonomic, sleep, and higher mental dysfunction. From the
few case reports that exist, it is clear that thymomas are
relatively frequent in these patients, but there have been no
comprehensive reviews as yet.
The most frequent antibody associated with thymomas
and CNS disturbance are VGKC antibodies. In studies de-
signed to determine the antigenic specificity of these antibod-
ies, we discovered that they are not directed against the
VGKCs themselves but to other proteins that are part of the
complexes that anchor VGKCs to the juxtaparanodes of
the axonal membrane or to synapses and are also likely to
modulate their function. In particular, we found that
Caspr2, a protein known to be complexed with VGKCs
and essential for their localization at the juxtaparanodes,25
is a target for antibodies in around 20% of the patients with
“VGKC” antibodies. The other major target for the
“VGKC” antibodies is leucine-rich glioma inactivated 1
(Lgi1), and our data show a very low rate of tumors in
association with Lgi1 antibodies.19
In this review, we summarize the clinical findings in
patients with high VGKC antibodies. Nineteen had Caspr2
antibodies, and this included six of the seven with thymomas.
These patients mainly had NMT with muscle fasciculations;
twitching and cramps; sweating; some autonomic distur-
bance; and often pain in the skin, muscle, or joints. Only one
patient in the thymoma group had Morvan disease, but two
patients without detected thymomas had this syndrome,
which includes the features of NMT with additional insom-
nia, confusion, and memory loss.
We did not find Caspr2 antibodies at detectable
levels in patients with typical MG and thymoma without
VGKC antibodies.19 It is difficult to predict from this
study, therefore, how common Caspr2 antibodies will be in
thymoma patients in general. MG is a much more frequent
thymoma-associated disease (at least 10 times higher in-
cidence, and around 10% of patients have thymomas) than
VGKC-Ab–associated CNS disorders. The incidence of
the syndromes associated with thymomas and these Caspr2
antibodies is probably low by comparison. Although
Caspr2 antibodies are an infrequent accompaniment to
thymoma, however, if a patient with thymoma has CNS or
peripheral nerve involvement, and if they have Caspr2
antibodies, one should assume that the thymoma may be
particularly active.
TABLE 3. Clinical Features of Patients with Thymomas and
Caspr2 Antibodies




Confusion or amnesia (MoS)
Hallucinations (MoS)
Insomnia (MoS)
Only one patient in this cohort had thymoma and MoS, but other patients with MoS
have been identified with thymomas and Caspr2 antibodies in subsequent studies (Irani
et al., unpublished data).
MoS, Morvan disease.












a The seventh tumor patient had an active endometrial carcinoma.
Caspr2, contactin-2 associated protein; MG, myasthenia gravis; NMT, neuromyo-
tonia; MoS, Morvan disease; LE, limbic encephalitis.
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